Sharon Lamb, partner, and David Gibson, senior associate, McDermott Will & Emery analyse the MHRA consultation to change the UK clinical trial regulations.
IMA Active and CONTINUUS Pharmaceuticals examine continuous manufacturing of solid oral dosage forms by integration of Raman spectroscopy to an Extrusion-Molding-Coating (EMC) unit.
Brice Ezzouaouy, senior product manager at Beckman Coulter Life Sciences, looks at the journey of the 2017 IVD Regulation and how it affects different aspects of the industry.
Innovative medicines can bring hope to people with rare diseases – let’s get them to patients, says Paul Catchpole director of Value and Access policy, Association of the British Pharmaceutical Industry.
Mark Arnold , MD of ONFAB, part of Envair Technology looks at how precision medicine is fuelling a growing demand for containment and cleanroom services.
Calvin Kim, senior director and head of IT Quality Systems & Validation at Samsung Biologics explores the fundamentals of data integrity and why a lack of critical strategic thinking could be affecting the success of implementing the technology.
Dr Amit Katiyar director, Pharma Services Group within Thermo Fisher Scientific on how a new method streamlines the development and quality control of biotherapeutics.
Mike Abbadessa, VP SME head of Medical Affairs at Within3, explores the benefits of pharma going virtual and whether the industry is prepared to do so.
European Pharmaceutical Manufacturer explores the rise of ketamine as treatment for depression and why a recent study shines hope on the drug being used to treat alcohol use disorder.
Ian Bolland is joined by Martin Gouldstone and Ray Valencia from Sensyne Health to explain more about the use of synthetic control arms, clinical trial transformation, speeding up the process and its SENSIGHT platform – which works within the NHS.
